UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Utilize your home equity as a powerful tool to eliminate debt. Explore options that can help you regain financial stability.
23,247 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
When a CEO with Nvidia’s clout announces a partner could be the next trillion-dollar company, investors listen. This ...
In a bold move amid a choppy market, a retiree turned down $100,000 in upfront dividend income to pursue a growth str...
Tenable’s stock jumped on Monday, marking a sharp continuation of a rally that started in the spring. This article di...
Three leading tech ETFs battle for AI-era glory. This story breaks down Nvidia exposure, valuation, and risk to answe...
A surge in demand for precision long-range rifles and components is reshaping defense investing. The niche market is ...
Apple launched the MacBook Neo at a budget price, signaling a potential breakthrough for Mac demand. This article bre...
MGK's gains have been propelled by a tight core of five megacaps, a dynamic that boosts returns but also raises risk ...
With unemployment data signaling a slower hiring cycle, investors are turning to enterprise automation. This article ...
Amazon is exploring a new growth lane: selling its Trainium AI chips to external customers. This article breaks down ...
Synopsys rides AI-driven demand in EDA and IP, delivering solid quarterly results and a robust backlog as the AI buil...
A fresh SEC filing shows AREX Capital Management opening a new stake in CALY with 453,000 shares worth about $5.29 mi...